Anti-VEGF the mainstay in DME management
As a second-line agent, steroids may be used in combination anti-VEGF


Dermot McGrath
Published: Monday, September 9, 2019
Although anti-vascular endothelial growth factor (anti-VEGF) drugs remain first-line agents in the management of diabetic macular oedema (DME), corticosteroids may still play a role in patients where anti-VEGF is contraindicated, unavailable or unaffordable, according to Sobha Sivaprasad MD.
“We know that the visual outcome will not be as good as anti-VEGF when using steroids. As a second-line agent, steroids may potentially be used in combination with an anti-VEGF agent. Although it has been recommended in pseudophakics who are non-responsive to anti-VEGF, the recent evidence from the Protocol U study suggests that very few patients will actually benefit,” she said.
In DME cases where there is no visual impairment, the best strategy is observation, said Dr Sivaprasad. She advised that any of the approved anti-VEGF agents should be administered on a tight treatment schedule in cases of DME with mild visual impairment. For patients whose visual acuity of 20/50 or worse, aflibercept should be the agent of choice as it performs better in more severe cases, she said.
For proliferative diabetic retinopathy (PDR), panretinal photocoagulation remains the standard of care in 2019.
“Anti-VEGF treatments may offer significant advantages but we need a good surveillance programme to be able to provide urgent anti-VEGF therapy if there is recurrence or reactivation of new vessels as non-perfusion continues to increase. The complications are disastrous if not treated properly in these cases,” she concluded.
Tags: anti-VEGF, corticosteroid use, diabetic macular oedema (DME)
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.